Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
RTOG Foundation, Inc.
Roswell Park Cancer Institute
Haukeland University Hospital
University of Chicago
University of Chicago
University of Chicago
University of Birmingham
University of Chicago
Mayo Clinic
University of Chicago
University of Pittsburgh
University of Chicago
First Affiliated Hospital Xi'an Jiaotong University
UNICANCER
Amsterdam UMC, location VUmc
University of Chicago
University of Miami
Montefiore Medical Center
Heidelberg University
Icahn School of Medicine at Mount Sinai
Children's Hospital of Philadelphia
University of Utah
Alliance for Clinical Trials in Oncology
Duke University
University of Leipzig
University of Chicago
Duke University
Duke University
Duke University
St. Jude Children's Research Hospital
Dartmouth-Hitchcock Medical Center
Consorzio Mario Negri Sud
Northwestern University